Stock Benefit Plans and Equity Transactions (Tables)

9 Months Ended

Sep. 30, 2018

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Total Stock Based Compensation

Total stock-based compensation for the three and nine months ended September 30, 2018 and 2017 is as follows (in thousands):

	Three Months Ended					Nine Months Ended
	September 30,					September 30,
	2018		2017			2018		2017
Cost of revenues	$	18	$	13		$	51	$	27
Research and development		179		(52	)		192		239
Sales and marketing		223		134			527		358
General and administrative		1,255		355			2,672		1,045
Total	$	1,675	$	450		$	3,442	$	1,669

Summary of Common Stock Reserved for Future Issuance

As of September 30, 2018, the Company had reserved shares of its common stock for future issuance as follows (in thousands):

	September 30, 2018
Stock options outstanding		4,880
Unvested restricted stock award		3,542
Employee stock purchase plan		232
Series A convertible preferred stock		2,022
Convertible Notes		988
Warrants outstanding		20,932
Distributor and surgeon royalty plans		4,000
Merger contingently issuable		887
Authorized for future grant under the Company equity plans		725
Total		38,208

Summary of Outstanding Warrants

A summary of all outstanding warrants is as follows:

	Number of Warrants		Strike Price
2017 Common Stock Warrants		3,757,000	$	2.00
2017 Banker Warrants		167,418	$	2.50
2018 Common Stock Warrants		13,471,851	$	3.50
Merger Warrants		2,200,000	$	3.50
Executive		1,327,434	$	5.00
Other		7,812	$	19.20
Total		20,931,515